FY2025 EPS Forecast for Kura Oncology Lifted by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Investment analysts at Brookline Capital Management increased their FY2025 earnings per share (EPS) estimates for Kura Oncology in a research note issued on Thursday, November 21st. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings of ($1.74) per share for the year, up from their prior forecast of ($2.27). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.42) per share. Brookline Capital Management also issued estimates for Kura Oncology’s FY2026 earnings at $0.95 EPS, FY2027 earnings at $3.16 EPS and FY2028 earnings at $5.97 EPS.

KURA has been the topic of several other reports. TD Cowen restated a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research note on Thursday, November 21st. JMP Securities restated a “market outperform” rating and issued a $32.00 price target on shares of Kura Oncology in a research report on Tuesday, November 19th. StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. Finally, Jefferies Financial Group reduced their target price on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, November 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $29.38.

Kura Oncology Stock Performance

Shares of NASDAQ:KURA opened at $10.75 on Monday. The stock has a market capitalization of $835.96 million, a P/E ratio of -4.56 and a beta of 0.86. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 1-year low of $9.06 and a 1-year high of $24.17. The business has a 50-day moving average price of $17.68 and a two-hundred day moving average price of $19.60.

Institutional Trading of Kura Oncology

A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in shares of Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock valued at $34,798,000 after buying an additional 41,535 shares during the period. Barclays PLC lifted its position in Kura Oncology by 104.5% in the 3rd quarter. Barclays PLC now owns 165,484 shares of the company’s stock valued at $3,234,000 after acquiring an additional 84,563 shares in the last quarter. Jane Street Group LLC boosted its stake in Kura Oncology by 36.7% in the 3rd quarter. Jane Street Group LLC now owns 126,085 shares of the company’s stock worth $2,464,000 after purchasing an additional 33,848 shares during the period. Point72 DIFC Ltd bought a new position in Kura Oncology during the 3rd quarter worth about $146,000. Finally, Point72 Asset Management L.P. bought a new position in Kura Oncology during the 3rd quarter worth about $3,695,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.